Takeda and Code Bio Form Partnership to Develop Gene Therapies

By PacConAdmin | February 23, 2022

Takeda Pharmaceuticals and Code Biotherapeutics are teaming up to develop gene therapies for treatment of rare diseases in a deal that is potentially worth up to $2 billion to Hatfield, Pa.-based Code Bio.
Source: Drug Industry Daily

Posted in Drug Industry Daily